{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T22:13:35Z","timestamp":1780697615702,"version":"3.54.1"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2014,11,20]],"date-time":"2014-11-20T00:00:00Z","timestamp":1416441600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2014,11,20]],"date-time":"2014-11-20T00:00:00Z","timestamp":1416441600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Castration-resistant prostate cancer (CRPC) cells acquire resistance to chemotherapy and apoptosis, in part, due to enhanced aerobic glycolysis and biomass production, known as the Warburg effect. We previously demonstrated that combination simvastatin (SIM) and metformin (MET) ameliorates critical Warburg effect-related metabolic aberrations of C4-2B cells, synergistically and significantly decreases CRPC cell viability and metastatic properties, with minimal effect on normal prostate epithelial cells, and inhibits primary prostate tumor growth, metastasis, and biochemical failure in an orthotopic model of metastatic CRPC, more effectively than docetaxel chemotherapy. Several modes of cell death activated by individual treatment of SIM or MET have been reported; however, the cell death process induced by combination SIM and MET treatment in metastatic CRPC cells remains unknown. This must be determined prior to advancing combination SIM and MET to clinical trial for metastatic CRPC. Treatment of C4-2B cells with combination 4\u2009<jats:italic>\u03bc<\/jats:italic>M SIM and 2\u2009mM MET (SIM+MET) led to significant G1-phase cell cycle arrest and decrease in the percentage of DNA-replicating cells in the S-phase by 24\u2009h; arrest was sustained throughout the 96-h treatment. SIM+MET treatment led to enhanced autophagic flux in C4-2B cells by 72\u201396\u2009h, ascertained by increased LC3B-II (further enhanced with lysosomal inhibitor chloroquine) and reduced Sequestosome-1 protein expression, significantly increased percentage of acidic vesicular organelle-positive cells, and increased autophagic structure accumulation assessed by transmission electron microscopy. Chloroquine, however, could not rescue CRPC cell viability, eliminating autophagic cell death; rather, autophagy was upregulated by C4-2B cells in attempt to withstand chemotherapy. Instead, SIM+MET treatment led to Ripk1- and Ripk3-dependent necrosis by 48\u201396\u2009h, determined by propidium iodide-Annexin V flow cytometry, increase in Ripk1 and Ripk3 protein expression, necrosome formation, HMGB-1 extracellular release, and necrotic induction and viability rescue with necrostatin-1 and Ripk3-targeting siRNA. The necrosis-inducing capacity of SIM+MET may make these drugs a highly-effective treatment for apoptosis- and chemotherapy-resistant metastatic CRPC cells.<\/jats:p>","DOI":"10.1038\/cddis.2014.500","type":"journal-article","created":{"date-parts":[[2014,11,20]],"date-time":"2014-11-20T15:05:14Z","timestamp":1416495914000},"page":"e1536-e1536","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":57,"title":["Combination simvastatin and metformin induces G1-phase cell cycle arrest and Ripk1- and Ripk3-dependent necrosis in C4-2B osseous metastatic castration-resistant prostate cancer cells"],"prefix":"10.1038","volume":"5","author":[{"given":"M A","family":"Babcook","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R M","family":"Sramkoski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H","family":"Fujioka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F","family":"Daneshgari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8916-6650","authenticated-orcid":false,"given":"A","family":"Almasan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Shukla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R R","family":"Nanavaty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,11,20]]},"reference":[{"key":"BFcddis2014500_CR1","unstructured":"American Cancer Society. Cancer Facts & Figures 2014. American Cancer Society: Atlanta, GA, USA, 2014."},{"key":"BFcddis2014500_CR2","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/j.juro.2013.05.005","volume":"190","author":"MS Cookson","year":"2013","unstructured":"Cookson MS, Roth BJ, Dahm P, Engstrom C, Freedland SJ, Hussain M et al. Castration-resistant prostate cancer: AUA Guideline. J Urol 2013; 190: 429\u2013438.","journal-title":"J Urol"},{"key":"BFcddis2014500_CR3","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1016\/j.clon.2013.03.002","volume":"25","author":"DA Loblaw","year":"2013","unstructured":"Loblaw DA, Walker-Dilks C, Winquist E, Hotte SJ, Genitourinary Cancer Disease Site Group of Cancer Care Ontario's Program in Evidence-Based Care. Systemic therapy in men with metastatic castration-resistant prostate cancer: a systematic review. Clin Oncol (R Coll Radiol) 2013; 25: 406\u2013430.","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"BFcddis2014500_CR4","doi-asserted-by":"publisher","first-page":"1502","DOI":"10.1056\/NEJMoa040720","volume":"351","author":"IF Tannock","year":"2004","unstructured":"Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004; 351: 1502\u20131512.","journal-title":"N Engl J Med"},{"key":"BFcddis2014500_CR5","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1126\/science.1160809","volume":"324","author":"MG Vander Heiden","year":"2009","unstructured":"Vander Heiden MG, Cantley LC, Thompson CB . Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 2009; 324: 1029\u20131033.","journal-title":"Science"},{"key":"BFcddis2014500_CR6","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.cmet.2012.12.001","volume":"17","author":"B Faubert","year":"2013","unstructured":"Faubert B, Boily G, Izreig S, Griss T, Samborska B, Dong Z et al. AMPK is a negative regulator of the Warburg effect and suppresses tumor growth in vivo. Cell Metab 2013; 17: 113\u2013124.","journal-title":"Cell Metab"},{"key":"BFcddis2014500_CR7","doi-asserted-by":"publisher","first-page":"5232","DOI":"10.1158\/0008-5472.CAN-04-0272","volume":"64","author":"JI Kreisberg","year":"2004","unstructured":"Kreisberg JI, Malik SN, Prihoda TJ, Bedolla RG, Troyer DA, Kreisberg S et al. Phosphorylation of Akt (Ser473) is an excellent predictor of poor clinical outcome in prostate cancer. Cancer Res 2004; 64: 5232\u20135236.","journal-title":"Cancer Res"},{"key":"BFcddis2014500_CR8","doi-asserted-by":"publisher","first-page":"e31919","DOI":"10.1371\/journal.pone.0031919","volume":"7","author":"M Mimeault","year":"2012","unstructured":"Mimeault M, Johansson SL, Batra SK . Pathobiological implications of the expression of EGFR, pAkt, NF-\u03baB and MIC-1 in prostate cancer stem cells and their progenies. PLoS One 2012; 7: e31919.","journal-title":"PLoS One"},{"key":"BFcddis2014500_CR9","doi-asserted-by":"publisher","first-page":"e14175","DOI":"10.1371\/journal.pone.0014175","volume":"5","author":"E Thysell","year":"2010","unstructured":"Thysell E, Surowiec I, H\u00f6rnberg E, Crnalic S, Widmark A, Johansson AI et al. Metabolomic characterization of human prostate cancer bone metastases reveals increased levels of cholesterol. PLoS One 2010; 5: e14175.","journal-title":"PLoS One"},{"key":"BFcddis2014500_CR10","doi-asserted-by":"publisher","first-page":"2288","DOI":"10.1158\/1535-7163.MCT-14-0451","volume":"13","author":"MA Babcook","year":"2014","unstructured":"Babcook MA, Shukla S, Fu P, Vazquez EJ, Puchowicz MA, Molter JP et al. Synergistic Simvastatin and Metformin Combination Chemotherapy for Osseous Metastatic Castration-Resistant Prostate Cancer. Mol Cancer Ther 2014; 13: 2288\u20132302.","journal-title":"Mol Cancer Ther"},{"key":"BFcddis2014500_CR11","doi-asserted-by":"publisher","first-page":"403","DOI":"10.2165\/00003088-199732050-00005","volume":"32","author":"H Lennern\u00e4s","year":"1997","unstructured":"Lennern\u00e4s H, Fager G . Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences. Clin Pharmacokinet. 1997; 32: 403\u2013425.","journal-title":"Clin Pharmacokinet."},{"key":"BFcddis2014500_CR12","doi-asserted-by":"publisher","first-page":"3101","DOI":"10.1007\/s00125-011-2311-5","volume":"54","author":"X Stephenne","year":"2011","unstructured":"Stephenne X, Foretz M, Taleux N, van der Zon GC, Sokal E, Hue L et al. Metformin activates AMP-activated protein kinase in primary human hepatocytes by decreasing cellular energy status. Diabetologia 2011; 54: 3101\u20133110.","journal-title":"Diabetologia"},{"key":"BFcddis2014500_CR13","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1016\/j.juro.2012.10.030","volume":"189","author":"YH Park","year":"2013","unstructured":"Park YH, Seo SY, Lee E, Ku JH, Kim HH, Kwak C . Simvastatin induces apoptosis in castrate resistant prostate cancer cells by deregulating nuclear factor-\u03baB pathway. J Urol 2013; 189: 1547\u20131552.","journal-title":"J Urol"},{"key":"BFcddis2014500_CR14","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.ejphar.2013.01.001","volume":"701","author":"RA Costa","year":"2013","unstructured":"Costa RA, Fernandes MP, de Souza-Pinto NC, Vercesi AE . Protective effects of l-carnitine and piracetam against mitochondrial permeability transition and PC3 cell necrosis induced by simvastatin. Eur J Pharmacol 2013; 701: 82\u201386.","journal-title":"Eur J Pharmacol"},{"key":"BFcddis2014500_CR15","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1016\/j.bbrc.2007.12.166","volume":"367","author":"M Araki","year":"2008","unstructured":"Araki M, Motojima K . Hydrophobic statins induce autophagy in cultured human rhabdomyosarcoma cells. Biochem Biophys Res Commun 2008; 367: 462\u2013467.","journal-title":"Biochem Biophys Res Commun"},{"key":"BFcddis2014500_CR16","doi-asserted-by":"publisher","first-page":"2823","DOI":"10.1093\/carcin\/bgt307","volume":"34","author":"T Akinyeke","year":"2013","unstructured":"Akinyeke T, Matsumura S, Wang X, Wu Y, Schalfer ED, Saxena A et al. Metformin targets c-MYC oncogene to prevent prostate cancer. Carcinogenesis 2013; 34: 2823\u20132832.","journal-title":"Carcinogenesis"},{"key":"BFcddis2014500_CR17","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/1475-2867-14-53","volume":"14","author":"A Takahashi","year":"2014","unstructured":"Takahashi A, Kimura F, Yamanaka A, Takebayashi A, Kita N, Takahashi K et al. Metformin impairs growth of endometrial cancer cells via cell cycle arrest and concomitant autophagy and apoptosis. Cancer Cell Int 2014; 14: 53.","journal-title":"Cancer Cell Int"},{"key":"BFcddis2014500_CR18","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1002\/iub.1213","volume":"65","author":"MG Bonini","year":"2013","unstructured":"Bonini MG, Gantner BN . The multifaceted activities of AMPK in tumor progression\u2014why the \"one size fits all\" definition does not fit at all? IUBMB Life 2013; 65: 889\u2013896.","journal-title":"IUBMB Life"},{"key":"BFcddis2014500_CR19","doi-asserted-by":"publisher","first-page":"2187","DOI":"10.1158\/1535-7163.MCT-12-1245","volume":"12","author":"H Lu","year":"2013","unstructured":"Lu H, Li X, Luo Z, Liu J, Fan Z . Cetuximab reverses the Warburg effect by inhibiting HIF-1-regulated LDH-A. Mol Cancer Ther 2013; 12: 2187\u20132199.","journal-title":"Mol Cancer Ther"},{"key":"BFcddis2014500_CR20","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1158\/1055-9965.EPI-07-0531","volume":"17","author":"A Hoque","year":"2008","unstructured":"Hoque A, Chen H, Xu XC . Statin induces apoptosis and cell growth arrest in prostate cancer cells. Cancer Epidemiol Biomarkers Prev 2008; 17: 88\u201394.","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"BFcddis2014500_CR21","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1186\/1471-2407-12-409","volume":"12","author":"A Goc","year":"2012","unstructured":"Goc A, Kochuparambil ST, Al-Husein B, Al-Azayzih A, Mohammad S, Somanath PR . Simultaneous modulation of the intrinsic and extrinsic pathways by simvastatin in mediating prostate cancer cell apoptosis. BMC Cancer 2012; 12: 409.","journal-title":"BMC Cancer"},{"key":"BFcddis2014500_CR22","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1007\/s00277-005-1065-x","volume":"84","author":"K Vermeulen","year":"2005","unstructured":"Vermeulen K, Van Bockstaele DR, Berneman ZN . Apoptosis: mechanisms and relevance in cancer. Ann Hematol 2005; 84: 627\u2013639.","journal-title":"Ann Hematol"},{"key":"BFcddis2014500_CR23","first-page":"255","volume":"34","author":"D Wlodkowic","year":"2012","unstructured":"Wlodkowic D, Skommer J, Darzynkiewicz Z . Cytometry of apoptosis. Historical perspective and new advances. Exp Oncol 2012; 34: 255\u2013262.","journal-title":"Exp Oncol"},{"key":"BFcddis2014500_CR24","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.toxlet.2012.10.008","volume":"215","author":"P Elumalai","year":"2012","unstructured":"Elumalai P, Gunadharini DN, Senthilkumar K, Banudevi S, Arunkumar R, Benson CS et al. Induction of apoptosis in human breast cancer cells by nimbolide through extrinsic and intrinsic pathway. Toxicol Lett 2012; 215: 131\u2013142.","journal-title":"Toxicol Lett"},{"key":"BFcddis2014500_CR25","first-page":"263","volume":"34","author":"AP Demchenko","year":"2012","unstructured":"Demchenko AP . The change of cellular membranes on apoptosis: fluorescence detection. Exp Oncol 2012; 34: 263\u2013268.","journal-title":"Exp Oncol"},{"key":"BFcddis2014500_CR26","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1002\/tox.21786","volume":"29","author":"CG Yedjou","year":"2014","unstructured":"Yedjou CG, Saeed MA, Hossain MA, Dorsey W, Yu H, Tchounwou PB . Basic apoptotic and necrotic cell death in human liver carcinoma (HepG2) cells induced by synthetic azamacrocycle. Environ Toxicol 2014; 29: 605\u2013611.","journal-title":"Environ Toxicol"},{"key":"BFcddis2014500_CR27","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.ymeth.2007.12.001","volume":"44","author":"DV Krysko","year":"2008","unstructured":"Krysko DV, Vanden Berghe T, D'Herde K, Vandenabeele P . Apoptosis and necrosis: detection, discrimination and phagocytosis. Methods 2008; 44: 205\u2013221.","journal-title":"Methods"},{"key":"BFcddis2014500_CR28","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1258\/ebm.2010.009369","volume":"235","author":"PS Koka","year":"2010","unstructured":"Koka PS, Mondal D, Schultz M, Abdel-Mageed AB, Agrawal KC . Studies on molecular mechanisms of growth inhibitory effects of thymoquinone against prostate cancer cells: role of reactive oxygen species. Exp Biol Med (Maywood) 2010; 235: 751\u2013760.","journal-title":"Exp Biol Med (Maywood)"},{"key":"BFcddis2014500_CR29","doi-asserted-by":"publisher","first-page":"3448","DOI":"10.1016\/j.bbamcr.2013.06.001","volume":"1833","author":"V Nikoletopoulou","year":"2013","unstructured":"Nikoletopoulou V, Markaki M, Palikaras K, Tavernarakis N . Crosstalk between apoptosis, necrosis and autophagy. Biochim Biophys Acta 2013; 1833: 3448\u20133459.","journal-title":"Biochim Biophys Acta"},{"key":"BFcddis2014500_CR30","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1016\/j.biocel.2012.11.001","volume":"45","author":"J Zhang","year":"2013","unstructured":"Zhang J, Yang Z, Xie L, Xu L, Xu D, Liu X . Statins, autophagy and cancer metastasis. Int J Biochem Cell Biol 2013; 45: 745\u2013752.","journal-title":"Int J Biochem Cell Biol"},{"key":"BFcddis2014500_CR31","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/1741-7007-9-39","volume":"9","author":"TE Hansen","year":"2011","unstructured":"Hansen TE, Johansen T . Following autophagy step by step. BMC Biol 2011; 9: 39.","journal-title":"BMC Biol"},{"key":"BFcddis2014500_CR32","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1007\/978-1-59745-157-4_4","volume":"445","author":"I Tanida","year":"2008","unstructured":"Tanida I, Ueno T, Kominami E . LC3 and Autophagy. Methods Mol Biol 2008; 445: 77\u201388.","journal-title":"Methods Mol Biol"},{"key":"BFcddis2014500_CR33","doi-asserted-by":"publisher","first-page":"542","DOI":"10.4161\/auto.4600","volume":"3","author":"N Mizushima","year":"2007","unstructured":"Mizushima N, Yoshimori T . How to interpret LC3 immunoblotting. Autophagy 2007; 3: 542\u2013545.","journal-title":"Autophagy"},{"key":"BFcddis2014500_CR34","doi-asserted-by":"publisher","first-page":"445","DOI":"10.4161\/auto.19496","volume":"8","author":"DJ Klionsky","year":"2012","unstructured":"Klionsky DJ, Abdalla FC, Abeliovich H, Abraham RT, Acevedo-Arozena A, Adeli K et al. Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy 2012; 8: 445\u2013544.","journal-title":"Autophagy"},{"key":"BFcddis2014500_CR35","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/S0076-6879(08)03612-4","volume":"452","author":"G Bj\u00f8rk\u00f8y","year":"2009","unstructured":"Bj\u00f8rk\u00f8y G, Lamark T, Pankiv S, \u00d8vervatn A, Brech A, Johansen T . Monitoring autophagic degradation of p62\/SQSTM1. Methods Enzymol 2009; 452: 181\u2013197.","journal-title":"Methods Enzymol"},{"key":"BFcddis2014500_CR36","doi-asserted-by":"publisher","first-page":"236","DOI":"10.4161\/auto.8.2.18600","volume":"8","author":"K Singh","year":"2012","unstructured":"Singh K, Matsuyama S, Drazba JA, Almasan A . Autophagy-dependent senescence in response to DNA damage and chronic apoptotic stress. Autophagy 2012; 8: 236\u2013251.","journal-title":"Autophagy"},{"key":"BFcddis2014500_CR37","doi-asserted-by":"publisher","first-page":"F244","DOI":"10.1152\/ajprenal.00033.2009","volume":"297","author":"S Periyasamy-Thandavan","year":"2009","unstructured":"Periyasamy-Thandavan S, Jiang M, Schoenlein P, Dong Z . Autophagy: molecular machinery, regulation, and implications for renal pathophysiology. Am J Physiol Renal Physiol 2009; 297: F244\u2013F256.","journal-title":"Am J Physiol Renal Physiol"},{"key":"BFcddis2014500_CR38","doi-asserted-by":"publisher","first-page":"3004","DOI":"10.1038\/onc.2013.256","volume":"33","author":"W He","year":"2014","unstructured":"He W, Wang Q, Srinivasan B, Xu J, Padilla MT, Li Z et al. A JNK-mediated autophagy pathway that triggers c-IAP degradation and necroptosis for anticancer chemotherapy. Oncogene 2014; 33: 3004\u20133013.","journal-title":"Oncogene"},{"key":"BFcddis2014500_CR39","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1007\/s10863-008-9155-9","volume":"40","author":"KA Oliveira","year":"2008","unstructured":"Oliveira KA, Zecchin KG, Alberici LC, Castilho RF, Vercesi AE . Simvastatin inducing PC3 prostate cancer cell necrosis mediated by calcineurin and mitochondrial dysfunction. J Bioenerg Biomembr 2008; 40: 307\u2013314.","journal-title":"J Bioenerg Biomembr"},{"key":"BFcddis2014500_CR40","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1016\/j.cell.2009.05.037","volume":"137","author":"YS Cho","year":"2009","unstructured":"Cho YS, Challa S, Moquin D, Genga R, Ray TD, Guildford M et al. Phosphorylation-driven assembly of the RIP1-RIP3 complex regulates programmed necrosis and virus-induced inflammation. Cell 2009; 137: 1112\u20131123.","journal-title":"Cell"},{"key":"BFcddis2014500_CR41","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.cell.2011.12.020","volume":"148","author":"FK Chan","year":"2012","unstructured":"Chan FK, Baehrecke EH . RIP3 finds partners in crime. Cell 2012; 148: 17\u201318.","journal-title":"Cell"},{"key":"BFcddis2014500_CR42","doi-asserted-by":"publisher","first-page":"E3109","DOI":"10.1073\/pnas.1301218110","volume":"110","author":"RJ Thapa","year":"2013","unstructured":"Thapa RJ, Nogusa S, Chen P, Maki JL, Lerro A, Andrake M et al. Interferon-induced RIP1\/RIP3-mediated necrosis requires PKR and is licensed by FADD and caspases. Proc Natl Acad Sci USA 2013; 110: E3109\u2013E3118.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFcddis2014500_CR43","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1186\/1471-2407-13-580","volume":"13","author":"Z Fu","year":"2013","unstructured":"Fu Z, Deng B, Liao Y, Shan L, Yin F, Wang Z et al. The anti-tumor effect of shikonin on osteosarcoma by inducing RIP1 and RIP3 dependent necroptosis. BMC Cancer 2013; 13: 580.","journal-title":"BMC Cancer"},{"key":"BFcddis2014500_CR44","doi-asserted-by":"publisher","first-page":"2074","DOI":"10.1038\/mt.2013.195","volume":"21","author":"LM Whilding","year":"2013","unstructured":"Whilding LM, Archibald KM, Kulbe H, Balkwill FR, \u00d6berg D, McNeish IA . Vaccinia virus induces programmed necrosis in ovarian cancer cells. Mol Ther 2013; 21: 2074\u20132086.","journal-title":"Mol Ther"},{"key":"BFcddis2014500_CR45","doi-asserted-by":"publisher","first-page":"31268","DOI":"10.1074\/jbc.M113.462341","volume":"288","author":"WJ Kaiser","year":"2013","unstructured":"Kaiser WJ, Sridharan H, Huang C, Mandal P, Upton JW, Gough PJ et al. Toll-like receptor 3-mediated necrosis via TRIF, RIP3, and MLKL. J Biol Chem 2013; 288: 31268\u201331279.","journal-title":"J Biol Chem"},{"key":"BFcddis2014500_CR46","doi-asserted-by":"publisher","first-page":"917","DOI":"10.4161\/onci.21244","volume":"1","author":"T Seya","year":"2012","unstructured":"Seya T, Shime H, Takaki H, Azuma M, Oshiumi H, Matsumoto M . TLR3\/TICAM-1 signaling in tumor cell RIP3-dependent necroptosis. Oncoimmunology 2012; 1: 917\u2013923.","journal-title":"Oncoimmunology"},{"key":"BFcddis2014500_CR47","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1007\/s00395-012-0270-8","volume":"107","author":"MI Oerlemans","year":"2012","unstructured":"Oerlemans MI, Liu J, Arslan F, den Ouden K, van Middelaar BJ, Doevendans PA et al. Inhibition of RIP1-dependent necrosis prevents adverse cardiac remodeling after myocardial ischemia-reperfusion in vivo. Basic Res Cardiol 2012; 107: 270.","journal-title":"Basic Res Cardiol"},{"key":"BFcddis2014500_CR48","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.cytogfr.2013.12.013","volume":"25","author":"K Moriwaki","year":"2014","unstructured":"Moriwaki K, Chan FK . Necrosis-dependent and independent signaling of the RIP kinases in inflammation. Cytokine Growth Factor Rev 2014; 25: 167\u2013174.","journal-title":"Cytokine Growth Factor Rev"},{"key":"BFcddis2014500_CR49","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.bbrc.2004.06.133","volume":"321","author":"X Xiang","year":"2004","unstructured":"Xiang X, Saha AK, Wen R, Ruderman NB, Luo Z . AMP-activated protein kinase activators can inhibit the growth of prostate cancer cells by multiple mechanisms. Biochem Biophys Res Commun 2004; 321: 161\u2013167.","journal-title":"Biochem Biophys Res Commun"},{"key":"BFcddis2014500_CR50","doi-asserted-by":"publisher","first-page":"a008763","DOI":"10.1101\/cshperspect.a008763","volume":"4","author":"BJ Altman","year":"2012","unstructured":"Altman BJ, Rathmell JC . Metabolic stress in autophagy and cell death pathways. Cold Spring Harb Perspect Biol 2012; 4: a008763.","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"BFcddis2014500_CR51","doi-asserted-by":"publisher","first-page":"9448","DOI":"10.1158\/0008-5472.CAN-09-1903","volume":"69","author":"D Wang","year":"2009","unstructured":"Wang D, Montgomery RB, Schmidt LJ, Mostaghel EA, Huang H, Nelson PS et al. Reduced tumor necrosis factor receptor-associated death domain expression is associated with prostate cancer progression. Cancer Res. 2009; 69: 9448\u20139456.","journal-title":"Cancer Res."},{"key":"BFcddis2014500_CR52","doi-asserted-by":"publisher","first-page":"2649","DOI":"10.1158\/1535-7163.MCT-08-0148","volume":"7","author":"C Wilson","year":"2008","unstructured":"Wilson C, Wilson T, Johnston PG, Longley DB, Waugh DJ . Interleukin-8 signaling attenuates TRAIL- and chemotherapy-induced apoptosis through transcriptional regulation of c-FLIP in prostate cancer cells. Mol Cancer Ther 2008; 7: 2649\u20132661.","journal-title":"Mol Cancer Ther"},{"key":"BFcddis2014500_CR53","doi-asserted-by":"publisher","first-page":"6465","DOI":"10.1016\/j.febslet.2005.10.041","volume":"579","author":"CP Lawrence","year":"2005","unstructured":"Lawrence CP, Chow SC . FADD deficiency sensitises Jurkat T cells to TNF-alpha-dependent necrosis during activation-induced cell death. FEBS Lett 2005; 579: 6465\u20136472.","journal-title":"FEBS Lett"},{"key":"BFcddis2014500_CR54","first-page":"Unit 7.5","volume":"Chapter 7","author":"Z Darzynkiewicz","year":"2001","unstructured":"Darzynkiewicz Z, Juan G . DNA content measurement for DNA ploidy and cell cycle analysis. Curr Protoc Cytom 2001; Chapter 7: Unit 7.5.","journal-title":"Curr Protoc Cytom"},{"key":"BFcddis2014500_CR55","doi-asserted-by":"publisher","first-page":"1458","DOI":"10.1038\/nprot.2006.238","volume":"1","author":"C Riccardi","year":"2006","unstructured":"Riccardi C, Nicoletti I . Analysis of apoptosis by propidium iodide staining and flow cytometry. Nat Protoc 2006; 1: 1458\u20131461.","journal-title":"Nat Protoc"},{"key":"BFcddis2014500_CR56","doi-asserted-by":"publisher","first-page":"1498","DOI":"10.3390\/cancers3021498","volume":"3","author":"KX Zhang","year":"2011","unstructured":"Zhang KX, Firus J, Prieur B, Jia W, Rennie PS . To die or to survive, a fatal question for the destiny of prostate cancer cells after androgen deprivation therapy. Cancers (Basel) 2011; 3: 1498\u20131512.","journal-title":"Cancers (Basel)"},{"key":"BFcddis2014500_CR57","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1007\/s10495-006-5881-9","volume":"11","author":"VP Skulachev","year":"2006","unstructured":"Skulachev VP . Bioenergetic aspects of apoptosis, necrosis and mitoptosis. Apoptosis 2006; 11: 473\u2013485.","journal-title":"Apoptosis"},{"key":"BFcddis2014500_CR58","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/S0076-6879(08)04013-5","volume":"453","author":"H Jiang","year":"2009","unstructured":"Jiang H, White EJ, Conrad C, Gomez-Manzano C, Fueyo J . Autophagy pathways in glioblastoma. Methods Enzymol 2009; 453: 273\u2013286.","journal-title":"Methods Enzymol"},{"key":"BFcddis2014500_CR59","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1002\/jemt.22287","volume":"76","author":"H Fujioka","year":"2013","unstructured":"Fujioka H, Tandler B, Consolo MC, Karnik P . Division of mitochondria in cultured human fibroblasts. Microsc Res Tech 2013; 76: 1213\u20131216.","journal-title":"Microsc Res Tech"}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/cddis2014500.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/cddis2014500","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/cddis2014500.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,5]],"date-time":"2023-01-05T23:20:45Z","timestamp":1672960845000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/cddis2014500"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,11,20]]},"references-count":59,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2014,11]]}},"alternative-id":["BFcddis2014500"],"URL":"https:\/\/doi.org\/10.1038\/cddis.2014.500","relation":{},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,11,20]]},"assertion":[{"value":"2 September 2014","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 October 2014","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 November 2014","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}